Clinical trials: Genetic Mutation
Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
The primary purpose of this study is to evaluate the safety of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with KRAS G12D-mutated metastatic colorectal cancer (CRC) or pancreatic…
- Trial name
- NCT07859085
- Testing
- GDC-7035, Panitumumab, mFOLFOX6
- Volunteers
- 388 people
- Sponsor
- Genentech, Inc.
Acute Myeloid Leukemia
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
This phase II trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant.
- Trial name
- NCT03728335
- Testing
- Enasidenib Mesylate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Colon Cancer
Multi Parametric Test Predicting the Risk of Colorectal Neoplasia Recurrence
This project is dedicated to identify the patients with possible higher risk of adenoma recurrence who should have follow-up colonoscopy in yearly interval.
- Trial name
- NCT03434925
- Testing
- Multi-targeted next generation sequencing
- Where
- Czechia
- Volunteers
- 200 people
- Sponsor
- Military University Hospital, Prague
Hereditary Breast Cancer
Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer
The overall purpose of the study is to evaluate a method for offering mutation analysis of BRCA1 and BRCA2 to all patients with newly diagnosed breast cancer, regardless of age at diagnosis and family history.
- Trial name
- BRCAsearch (NCT02557776)
- Testing
- Germline genetic testing of BRCA1 and BRCA2
- Where
- 2 sites in Sweden
- Volunteers
- 542 people
- Sponsor
- Lund University
Amyotrophic Lateral Sclerosis
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for people with a certain type of amyotrophic lateral sclerosis, also known as…
- Trial name
- NCT07223723
- Testing
- Tofersen
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Biogen
Pheochromocytoma, Paraganglioma
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous.
- Conditions
- Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome, Associated Conditions
- Trial name
- NCT03160274
- Testing
- Genetic screening
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Advanced Cancer, Metastatic Cancer
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART4215 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Breast Cancer
- Trial name
- NCT04991480
- Testing
- ART4215, Talazoparib, Niraparib
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 93 people
- Sponsor
- Artios Pharma Ltd
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Non-squamous NSCLC, HER2 Exon 20 Mutation
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a…
- Trial name
- PYRAMID-1 (NCT04447118)
- Testing
- Pyrotinib, Docetaxel
- Where
- 102 sites in United States, Australia and 11 more
- Volunteers
- 151 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer
This is a multicenter phase II study on trabectedin in advanced or recurrent ovarian cancer patients with BRCA mutation and BRCAness phenotype.
- Trial name
- MITO15 (NCT01772979)
- Testing
- Trabectedin
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Catholic University of the Sacred Heart
Tumor, Brain Tumor
Utility of Primary Glioblastoma Cell Lines
In this study, the characterization of human malignant glioma cell lines is described. After mechanical and enzymatic digestion of glioblastoma human biopsies from Neuromed IRCCS Neurosurgery patients, the investigators analyzed…
- Trial name
- NCT04180046
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Neuromed IRCCS
Breast Cancer
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
The researchers are doing this study to look at changes in Ki67 expression after at least 2 weeks of endocrine therapy in people with ER+/HER2- breast cancer undergoing cancer removal surgery.
- Trial name
- NCT06127979
- Testing
- blood draw
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed or Advanced Non-small Cell Lung Cancer
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
To evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of Almonertinib combined with SHR-1701 in relapsed or advanced NSCLC To evaluate the efficacy of Almonertinib combined with SHR-1701 in the…
- Trial name
- NCT05503888
- Testing
- Almonertinib combined with SHR-1701, Almonertinib
- Volunteers
- 160 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine.
- Conditions
- Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02719574
- Testing
- FT-2102 (olutasidenib), Azacitidine, Cytarabine
- Where
- 60 sites in United States, Australia and 7 more
- Volunteers
- 336 people
- Sponsor
- Forma Therapeutics, Inc.
Breast Cancer
Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study
All participants will read a decision aid (DA) communicating evidence about mammography screening benefits and harms. Participants' evaluations of that evidence will be assessed, along with their screening intentions and receipt…
- Trial name
- NCT05838417
- Testing
- REDS survey
- Where
- 2 sites in United States
- Volunteers
- 499 people
- Sponsor
- University of Colorado, Denver
Astrocytoma, Astrocytic Tumors
Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma
This study looked at a type of brain tumor called astrocytoma and how specific genetic changes like IDH mutations affect patients outcomes.
- Conditions
- Astrocytoma, Astrocytic Tumors, Astrocytoma of Brain
- Trial name
- NCT06620926
- Testing
- IDH mutant-type, IDH wild-type
- Where
- Egypt
- Volunteers
- 811 people
- Sponsor
- asmaa salama ibrahim
HER2-positive Breast Cancer, HER2 Low
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.
- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985
- Trial name
- NCT04602117
- Testing
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- QuantumLeap Healthcare Collaborative
Charcot-Marie-Tooth Disease Type 2D
Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D)
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Charcot-Marie-Tooth disease type 2D (CMT2D) due to a pathogenic, de novo deletion mutation in…
- Trial name
- NCT07226297
- Testing
- nL-GARS1-001
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- n-Lorem Foundation
Inherited Retinal Dystrophy
Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy
Up to nine subjects who have participated in the earlier LX101 clinical study, and who meet all study eligibility criteria, will receive LX101 administration in the previously uninjected, contralateral eye to evaluate the safety…
- Trial name
- NCT06212297
- Testing
- LX101
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Innostellar Biotherapeutics Co.,Ltd
Non-small Cell Lung Cancer
To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)
To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as first-line treatment in patients with KeAP1-mutated advanced or postoperative recurrent non-small cell lung cancer.
- Trial name
- NCT06341660
- Testing
- cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.